Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPG-178 is a neutral, synthetic self-assembling peptide (SAP) hydrogel developed as a versatile scaffold for tissue engineering and regenerative medicine. It consists of short peptides that spontaneously form a stable, transparent nanofiber hydrogel in a neutral pH environment upon exposure to electrolytes. Unlike earlier SAP hydrogels such as RADA16, which are acidic, SPG-178 maintains a neutral pH, significantly reducing tissue irritation and inflammation. The material is non-biological, non-cytotoxic, and biocompatible, making it suitable for a wide range of clinical applications. It has been investigated as a topical hemostatic agent, a vitreous substitute in ophthalmic surgery, a scaffold for bone and periodontal regeneration, a neuroprotective agent in spinal cord injury, and a tool to prevent pancreatic fistulas after surgery. Its mechanical properties, including viscoelasticity, can be tuned by adjusting peptide and salt concentrations to suit specific biomedical needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SPG-178.